General Practitioner
eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors Publication charge
Editorial System
Submit your Manuscript
Search
3/2025
vol. 11
 
Share:
Send email
Share:
abstract:

Oral semaglutide in the treatment of patients with type 2 diabetes – efficacy and mechanism of action

Anna Łosiowska
1
,
Piotr Gręblowski
1
,
Daria Zawodnik
1
,
Karolina Kłoda
1

  1. Polskie Towarzystwo Medycyny Rodzinnej
Online publish date: 2025/09/01
View full text Get citation
 
Oral semaglutide belongs to the group of glucagon-like peptide-1 (GLP-1) analogues and is used in the treatment of patients with type 2 diabetes. Patients using the drug achieve clinical improvement through normoglycemic effects, support for weight loss, and nephroprotective effects of semaglutide. It also has a number of other properties that can have a beneficial effect on the patient’s body, including preventing progression and exacerbation of complications and comorbidities, and reducing cardiovascular risk, including the risk of mortality. The article presents the mechanism of action of semaglutide, as well as the effectiveness of its oral form.
keywords:

type 2 diabetes, complications, cardiovascular risk, treatment
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.